Besides, Masahiro et al. reported that 87.0% (328/377) of patients with ND-CML-CP treated with nilotinib achieved EMR at 3 months (BCR::ABL1 IS <10%), which indicated a significantly superior PFS compared with those without EMR after a 5-year follow-up (p < 0.0001) (20). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.